In February 2023, the FDA approved sacituzumab govitecan for use in locally advanced/metastatic, unresectable HR-positive HER2-negative breast cancers, on the basis of the TROPICS-02 trial, which saw improvement in PFS (5.5 months vs. 4 months) and OS (14.4 months vs. 11.2 months) when compared to single-agent chemotherapy [68]. Here, ERBB2 is linked to breast cancer.